Welcome to our dedicated page for Legend Biotech news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech stock.
Legend Biotech Corporation (NASDAQ: LEGN) generates frequent news as a global cell therapy company focused on CAR‑T treatments for cancer. News coverage for Legend Biotech often centers on CARVYKTI® (ciltacabtagene autoleucel; cilta‑cel), its BCMA‑targeted CAR‑T cell therapy for relapsed or refractory multiple myeloma, as well as updates on its broader pipeline of cell therapy programs.
Investors and observers following LEGN news can expect regular announcements on clinical data from the CARTITUDE program in multiple myeloma, including long‑term progression‑free survival results and analyses of earlier‑line use. Company press releases also highlight presentations at major medical meetings such as the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the European Hematology Association (EHA), where Legend Biotech shares outcomes from CARVYKTI and investigational candidates like LUCAR‑G39D, LB2102, and LB1908.
Legend Biotech’s news flow includes regulatory milestones, such as FDA and European Commission label updates for CARVYKTI to incorporate overall survival data and new safety information. The company also reports on manufacturing and infrastructure developments, including expansion of its Raritan, New Jersey cell therapy facility and commercial production in Ghent, Belgium, which are intended to support growing global demand.
Quarterly earnings releases and related Form 6‑K filings provide financial updates on collaboration revenue from CARVYKTI, license revenue from agreements with partners, operating expenses, cash and time deposits, and progress toward profitability. Corporate news items may also cover executive appointments, participation in investor conferences, and strategic priorities outlined at healthcare investment events.
For users tracking LEGN, this news page offers a centralized view of Legend Biotech’s clinical, regulatory, manufacturing, and financial announcements, helping contextualize the company’s evolution in the cell therapy and oncology landscape.
GenScript Biotech reported strong annual results for 2022, with a revenue of approximately US$625.7 million, marking a 27.7% increase from US$490.1 million in 2021. The non-cell therapy segment achieved external revenue of US$509.0 million, up 19.8%, while cell therapy revenue surged by 70% to US$116.7 million. Adjusted net profit for the non-cell therapy sector rose by 31.4% to US$62.4 million, while the cell therapy sector faced an adjusted net loss of approximately US$422.1 million. The report highlights significant growth in biologics development and industrial synthetic biology, alongside an increased backlog in biologics.
Legend Biotech Corporation (NASDAQ: LEGN) reported its full year 2022 financial results, showcasing significant milestones such as FDA and MHLW approvals for CARVYKTI® (ciltacabtagene autoleucel) and the acceptance of its NDA in China. Total revenue reached $117.0 million, a substantial increase from $68.8 million in 2021, driven by CARVYKTI® sales. However, the company reported a net loss of $446.3 million, slightly higher than the previous year's loss of $403.6 million. Increased R&D and administrative expenses were noted, impacting financial performance. The company aims to expand its manufacturing and clinical program, focusing on bringing CARVYKTI® to more patients.
The report titled 'Germany Cell and Gene Therapy Market - Focused Insights 2023-2028' reveals that the market was valued at
Key drivers include an increase in target patient populations and robust regulatory support. Zolgensma is highlighted as the first blockbuster therapy, having generated
The "Europe Cell and Gene Therapy Market - Focused Insights 2023-2028" report, added by ResearchAndMarkets, provides a comprehensive analysis of the European market valued at $2.17 billion in 2022 and projected to reach $15.15 billion by 2028, marking a 38.20% CAGR. Key highlights include Zolgensma's revenue of $1.37 billion in 2022, with potential growth to $5.00 billion by 2026. The report examines over 1,564 clinical trials in Europe and profiles leading companies like Novartis, Gilead Sciences, and Legend Biotech. It emphasizes the importance of government and academic financing, contributing to market growth.
Venatorx Pharmaceuticals announces a significant change in its Board of Directors.
Legend Biotech Corporation (NASDAQ: LEGN), based in Somerset, NJ, has announced its participation in two upcoming investor conferences. The first is the Cowen 43rd Annual Healthcare Conference in Boston, MA on March 7, 2023, at 9:50 AM ET, featuring CEO Ying Huang, Ph.D. The second event is the Barclays Global Healthcare Conference in Miami, FL on March 14, 2023, at 10:15 AM ET, also presented by Dr. Huang. Legend Biotech focuses on developing novel therapies for life-threatening diseases through advanced cell therapies.
Legend Biotech Corporation (NASDAQ: LEGN) announced on February 17, 2023 that it has regained compliance with Nasdaq Listing Rules 5250(c)(2). This follows a notice of noncompliance received on January 6, 2023, due to the company’s failure to file an interim balance sheet and income statement for the quarter ended June 30, 2022. After a planned restatement of audited financial statements, the necessary Form 6-K was filed on February 17, 2023, addressing the compliance issue. Legend Biotech focuses on developing advanced cell therapies to treat life-threatening diseases.
Legend Biotech Corporation (NASDAQ: LEGN) announced that its Phase 3 study CARTITUDE-4, evaluating CARVYKTI® for relapsed and lenalidomide-refractory multiple myeloma, successfully met its primary endpoint. The study showed a statistically significant improvement in progression-free survival (PFS) compared to standard therapy during the first pre-specified interim analysis. Following an independent data monitoring committee's recommendation, the study has been unblinded. This international trial is the first to compare CAR-T therapy to standard treatments in this patient group. Results will be presented at an upcoming medical meeting, potentially guiding future regulatory discussions.
Legend Biotech Corporation (NASDAQ: LEGN) received a notice from Nasdaq on January 6, 2023, indicating non-compliance with Listing Rules due to a failure to file the interim balance sheet and income statement for the quarter ended June 30, 2022. The deadline for compliance was December 31, 2022, which has not been met due to a planned restatement of prior financial statements. The company has 60 days from the notice to submit a compliance proposal, with a potential extension to June 29, 2023, if accepted.
Legend Biotech Corporation (NASDAQ: LEGN) has announced its participation in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA. CEO Ying Huang, PhD, will present on Tuesday, January 10, 2023, at 2:15 PM Pacific Time. The company is focused on developing novel therapies for life-threatening diseases, leveraging advanced cell therapies, including CAR T-cell and NK cell-based immunotherapy. Legend Biotech, headquartered in Somerset, New Jersey, strives to discover cutting-edge therapeutics globally.